These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26548422)

  • 1. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
    Shaefer CF; Anderson J
    Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
    Umpierrez GE; Bailey TS; Carcia D; Shaefer C; Shubrook JH; Skolnik N
    J Diabetes; 2018 Feb; 10(2):94-111. PubMed ID: 28581207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
    Porcellati F; Lucidi P; Bolli GB; Fanelli CG
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
    Robertson C
    Diabetes Educ; 2006; 32(3):423-32. PubMed ID: 16772658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
    Trautmann ME; Vora J
    Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
    Perreault L; Rodbard H; Valentine V; Johnson E
    Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of timely basal insulin control in patients with type 2 diabetes.
    Lovre D; Fonseca V
    J Diabetes Complications; 2015 Mar; 29(2):295-301. PubMed ID: 25536866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining basal insulin analogs with glucagon-like peptide-1 mimetics.
    Perfetti R
    Diabetes Technol Ther; 2011 Sep; 13(9):873-81. PubMed ID: 21711120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
    Aronson R
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rationale for combining GLP-1 receptor agonists with basal insulin.
    Cohen ND; Audehm R; Pretorius E; Kaye J; Chapman LH; Colagiuri S
    Med J Aust; 2013 Aug; 199(4):246-9. PubMed ID: 23984780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using prandial insulin to achieve glycemic control in type 2 diabetes.
    Dailey GE
    J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.